Cisplatin + nintedanib + pemetrexed + placebo

Author: ewzi

August undefined, 2024

WebNov 1, 2024 · This concept was based on the following reasoning: pemetrexed plus cisplatin is a standard first-line regimen in MPM; a phase III trial in advanced MPM confirmed that treatment with pemetrexed as a second-line regimen resulted in improved progression-free survival (PFS) over best supportive care. 5 In a Dutch single-arm … WebNintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, …

Use of Nintedanib and Pirfenidone in Non–Idiopathic Pulmonary …

WebPatients were randomly assigned in a 1:1 ratio to receive nintedanib or placebo. Randomization was stratiﬁed by histology (epithelioid or biphasic). Treatment with … WebPatients received oral nintedanib (150 mg or 200 mg twice daily for 12 weeks) or placebo, in addition to usual neoadjuvant chemotherapy with intravenous gemcitabine 1000 mg/m 2 on days 1 and 8 and intravenous cisplatin 70 mg/m 2 on day 1 of a 3-weekly cycle. The primary endpoint was pathological complete response rate, assessed at cystectomy or ... greer lime company riverton wv

NSCLC Medikamentöse Therapie des metastasierten oder …

WebNov 1, 2024 · Grosso, F. et al. Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: Phase II results from the randomized placebo-controlled LUME-meso trial. J. Clin. WebThe pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of malignant pleural mesothelioma (MPM). The second-line (SL) c… WebDec 19, 2016 · ITT analysis of the primary end point showed that treatment with nintedanib plus pemetrexed resulted in a significant prolongation of PFS compared with placebo plus pemetrexed (4.4 vs. 3.6 months with a HR of 0.83 and a p value of 0.04). fobt instructions

Pemetrexed Injection: Package Insert - Drugs.com

Nintedanib in combination with pemetrexed and cisplatin …

WebMay 16, 2013 · This randomized, double-blinded study evaluated nintedanib – a triple angiokinase inhibitor – plus pemetrexed compared to pemetrexed plus placebo in patients with advanced non-squamous NSCLC not responding to, or who progressed after, first-line chemotherapy. 20 LUME-Lung 2 did not pass the pre-defined interim futility analysis from ... WebMay 30, 2024 · Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). Anna K. Nowak. x. Anna K. Nowak. Search for articles by this author , Federica Grosso. x ... fobt indicationWebApr 16, 2024 · Patients in the pembrolizumab-combination group received pemetrexed, a platinum-based drug, and pembrolizumab; those in the placebo-combination group received pemetrexed, a platinum-based … fobt insure one spanish instructions

"WebNintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, … " - Cisplatin + nintedanib + pemetrexed + placebo

Cisplatin + nintedanib + pemetrexed + placebo

Tumour Treating Fields for mesothelioma - The Lancet Oncology

WebDec 9, 2024 · Scagliotti GV, et al. Nintedanib in Combination with Pemetrexed and Cisplatin for Chemotherapy-Naive Patients with Advanced Malignant Pleural … WebMay 15, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural …

Did you know?

WebDec 4, 2014 · At least one dose reduction of nintedanib or placebo was required by 18.6% and 6.3% of patients in the nintedanib plus docetaxel and placebo plus docetaxel groups, respectively. Gastrointestinal AEs … WebThis is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by …

WebGültigkeitsbereich: Leitlinie Tumorzentrum Oberösterreich Bronchuskarzinom Paz-Ares L, Gridelli C et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non- small-cell lung cancer (PARAMOUNT): a double-blind ... WebJul 5, 2024 · Nintedanib, oral, triple angiokinase inhibitor of VEGFR, PDGFR, and FGFR, has been investigated in a phase II study randomizing patients who received first line pemetrexed-cisplatin between nintedanib or placebo. Recently, preliminary data were reported on the additional effect of nintedanib added to cisplatin/pemetrexed.

WebThis study enrolled 87 participants with chemo-naïve unresectable MPM, ECOG performance status 0–1, and non-sarcomatoid disease histology. Patients were randomized 1:1, double blinded, to cisplatin/pemetrexed with nintedanib 200 mg b.d. or placebo, and nintedanib or placebo was subsequently continued as monotherapy until progression. WebJul 1, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double …

WebSep 18, 2024 · This study aims to evaluate the safety of nintedanib when used in combination with pemetrexed and cisplatin in patients with unresectable MPM. This randomized, double-blind, placebo-controlled, phase 3 trial included a total of 458 patients with unresectable epithelioid MPM.

WebJ Clin Oncol 31(23):2895–2902 CrossRef Paz-Ares LG et al (2013) PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. fobt in medical termsWebMar 27, 2024 · For unresectable MPM, a regimen of pemetrexed (Pem) and cisplatin (Cis) was approved as the standard of care in first-line treatment by the FDA in 2004 . Currently, numerous studies are being conducted to explore the efficacy of novel agents and regimens for MPM first-line treatment. ... Regardless, any kind of therapy other than placebo may … greer limestone wv pricesWebA subsequent analysis of the available intent-to-treat population based on independent review data showed a PFS benefit for patients treated with nintedanib plus pemetrexed compared with placebo plus pemetrexed (median PFS of 4.4 months versus 3.6 months; hazard ratio [HR] of 0.83 with a 95% confidence interval [CI] of 0.70–0.99; P=0.04), but ... greer little theaterWebOct 1, 2024 · PDF On Oct 1, 2024, Federica Grosso and others published SPS-7Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial Find ... fobt in medicalWebJul 24, 2013 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double … fobt in medical termWebApr 4, 2024 · Eligible patients with previously untreated metastatic nonsquamous non–small-cell lung cancer without EGFR/ALK alterations were randomly assigned 2:1 to pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles with pemetrexed and investigator's choice of carboplatin/cisplatin for four cycles, followed … greer library scWebApr 1, 2024 · Request PDF On Apr 1, 2024, Antoinette J. Wozniak and others published Short report of a phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM) Find, read and cite all ... fobt insure tests